Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1
2(100.0%)
2Total
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT04329728Phase 1Recruiting

The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies

Role: lead

NCT04366115Phase 1Not Yet Recruiting

Evaluating AVM0703 for Treatment of COVID-19 or Influenza-mediated ARDS

Role: lead

NCT05974410Unknown

Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients

Role: lead

All 3 trials loaded